We’re excited to announce that Berkeley Lights and IsoPlexis are moving forward together as PhenomeX, a premier functional cell biology company. Visit Site

Hear from BLI experts Renee Tobias and Anupam Singhal about the unique benefits to leveraging a single platform for both the identification of promising candidates and the production of leading therapeutic molecules.

Please fill out the following form to access this resource:

First Name*
Last Name*
Email Address*
Phone Number*
City*
Country*
State*
Company/Institute*
CAPTCHA

Related Resources

View All Resources

Cell Line Development Beacon System

APP NOTE: Identify Top Producing Clones with Favorable Product Quality Attributes

Identify clones with favorable growth, titer, and product quality attributes prior to scale up
Go from transfected pools to top clones in under one week for a wide variety of protein therapeutics, including protein-based vaccines,
enzymes and bispecific molecules
Cloning efficiencies 5x greater than FACS and 10x greater than limiting dilution, and >99% monoclonality assurance

Antibody Discovery

SynBioBeta Live Roundtable: Can Humanity Build a Global Antibody Defense Barrier Against Future Pandemics?

Listen to the world’s leading experts on antibody discovery to discuss how we can build a global defensive barrier to find new therapeutic antibodies against the coronavirus and future pathogens.

Antibody Discovery

Webinar: Looking to the Future: What’s next in Antibody Therapeutics

At the 2021 AE&T EU conference, Tracey Mullens, CEO of Abveris, and Brian Walters, CEO of Genovac, joined John Proctor, SVP Antibody Therapeutics, for a discussion about the evolving landscape of antibody therapeutics, the technologies they have turned to address today’s complex targets, and how they are preparing for tomorrow’s challenges.